Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
According to IQVIA MAT data for June 2025, the product recorded annual sales of 10.9 million Canadian dollars in Canada. With this approval, Zydus, along with its subsidiaries and affiliates, will be able to market the drug in Canada, further strengthening its presence in the North American generics market.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company’s consolidated net profit rose 3.3% to Rs 1,466.80 crore on a 7% rise in revenue from operations to Rs 6,467 crore in Q1 FY26 over Q1 FY25.
Shares of Zydus Lifesciences fell 0.22% to Rs 992.15 on the BSE.
Zydus Lifesciences has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.
Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.
ZDS- Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ.
Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Deflazacort oral suspension (USRLD: Emflaza Oral Suspension, 22.75 mg/mL).
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy (DMD) in patients 5 years of age and older.
Deflazacort belongs to a group of medications called steroids. It works by decreasing inflammation and slowing down an overactive immune system. Deflazacort oral suspension will be produced at Doppel, Italy.